ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events
December 17, 2018The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI. -
Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events
December 17, 2018The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.
Pharma Sources Insight January 2025
